FDA recall record

Gabapentin Tablets, USP 600 mg recall — FDA D-0570-2023

Product mixup: one foreign tablet found in product.

Class IIIclassification
D-0570-2023official record ID
May 17, 2023report date

Recall record at a glance

Official recordD-0570-2023
CategoryDrug Recalls
ClassificationClass III
FDA record statusTerminated
Recalling firmThe Harvard Drug Group
Report dateMay 17, 2023
Recall initiation dateApr 24, 2023
Quantity3984 cartons
LocationLa Vergne, TN, United States

Official product description

Gabapentin Tablets, USP 600 mg, packaged in Cartons of 100 tablets (10 tablets per blister pack x 10), Rx Only, Distributed by: Aurobindo Pharma USA, Inc. East Windsor, NJ 08520 Distributed by: Major Pharmaceuticals 17177 N Laurel Park Dr., Suite 233 Livonia, MI 48152 USA, NDC 0904-6823-61

Why the product was recalled

Product mixup: one foreign tablet found in product.

Distribution information

USA Nationwide

How to read the classification

FDA Class III generally covers situations in which use of or exposure to the product is not likely to cause adverse health consequences. The classification displayed here is taken from the FDA enforcement record.

Additional record details

Recall type: Voluntary: Firm initiated. Initial notification: Letter.

What to do next

If you believe you have the recalled product, use the recall number and firm information above to confirm the official notice and follow the instructions issued by the FDA, recalling firm, retailer or product manufacturer. For drugs and medical devices, decisions about treatment or medical care should be discussed with a qualified health professional.

About this record

Recall Lookup USA preserves the most complete source information successfully retrieved. We do not create missing facts or infer affected lots or VINs. The official record may still change, so use the identifier above when verifying current instructions.

FDA source limitation: openFDA enforcement reports are a reference dataset, not a live public-alert or recall-lifecycle service. FDA notes that enforcement-report status may not be updated after classification. Confirm current actions with the FDA, recalling firm or appropriate healthcare professional when relevant.

Related recall records

Other records from the same recalling company are shown first when available.